Skip to main content
EVCM $10.21 +0.15%
EVCM logo

EVCM · EverCommerce Inc.

Track EVCM — free
$10.21 +0.02 (+0.15%) At close · Aug 17
Market Cap
$1.79B
Shares
176.67M
All earnings calls

Earnings call · FY2025 Q4

EverCommerce Inc. Q4 FY2025 Earnings Call

EverCommerce Inc. Q4 FY2025 Earnings Call

Concluded Mar 12, 2026 Audio replay
Mar 12, 2026 34:42 32 turns
Period
FY2025 Q4
Runtime
34:42
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

EverCommerce reported Q4 2025 revenue of $151.2 million (up 5.2% YoY), beating the midpoint of guidance, with Adjusted EBITDA of $44.2 million (29.2% margin) exceeding the top end of guidance. The company is guiding FY2026 revenue to $612–$632 million and Adjusted EBITDA to $183–$191 million, while continuing to invest in AI capabilities across its EverHealth and EverPro platforms.

EverHealth vertical 36 AI initiatives and roadmap 21 Payments and TPV growth 21 EverPro vertical and field services 19 Operating leverage and efficiency 18 Capital return and balance sheet 9

Management tone

Confident

Net tone +62 · low hedging

Grounding quotes
  • “2025 was a year of tremendous positive change for EverCommerce.”
  • “we met or exceeded our financial targets for the year, demonstrating our continued focus on financial performance.”
  • “Adjusted EBITDA for the quarter of $44.2 million beat the top end of our guidance range, representing a 29.2% margin.”
  • “We do expect reacceleration from Q1 through the rest of the year.”

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $151.15M +5.2% YoY
Net income · derived Q4 $6.04M

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q4 revenue of $151.2M exceeded the midpoint of guidance and grew 5.2% YoY, with Adjusted EBITDA of $44.2M beating the top end of guidance at a 29.2% margin
  • Sold the underperforming Marketing Technology business and acquired Xyrotoc (Zyra Talk) to strengthen the AI foundation
  • Repurchased 8.2M shares for ~$85M in 2025, including 2.5M shares for $24.8M in Q4; Board added $50M to the repurchase authorization with $47.7M remaining
  • LTM pro forma revenue of $591.7M (up 6.4% YoY) with 30.7% Adjusted EBITDA margin and annualized TPV expanded to $13B
  • EverHealth AI scribe received a 99.1% customer satisfaction rate and is moving to general availability by end of Q1 2026
  • FY2026 guidance calls for revenue of $612–$632M and Adjusted EBITDA of $183–$191M, implying continued growth and margins above 30%

Risks & pressure points

  • Net income from continuing operations fell to $5.7M ($0.03/share) in Q4 2025 from $12.5M ($0.06/share) in Q4 2024
  • Q1 2026 revenue guidance of $145.5–$148.5M represents a sequential step-down from Q4's $151.2M
  • Management cited deliberate execution decisions, including investments in payments and go-to-market, as drivers of the Q1 step-down, with reacceleration expected later in the year
  • Adjusted EBITDA in Q4 was roughly flat at $44.2M versus $44.1M in Q4 2024, despite revenue growth
  • Management acknowledged low visibility into certain non-GAAP charges, limiting forward GAAP reconciliation

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Mar 12, 2026.

Metric Guided
Revenue
First Quarter 2026
$145.5M – $148.5M
Adjusted EBITDA
First Quarter 2026
$39M – $41M
Revenue
Full Year 2026
$612M – $632M
Adjusted EBITDA
Full Year 2026
$183M – $191M

Quarter detail

How the reported period landed and where the business moved.

Result vs. guidance

Revenue Within

Capital returned

Buybacks · derived
$24.64M
Full-screen source Call document